Krka (KRK) H2 2024 earnings summary

Executive summary

• Revenue grew 6% year-over-year to €1,909.5 million, with net profit up 14% to €356.2 million, driven by strong sales in most regions and controlled cost growth.

• The Group expanded its product portfolio with 22 new products and established a joint venture in India, aiming to enhance production for new and existing markets.

• Investments totaled €117 million, focusing on capacity expansion, sustainability, and operational efficiency.

• The S&P Global CSA sustainability score improved, ranking Krka among the top 10% in the pharmaceutical industry.

Financial highlights

• Revenue: €1,909.5 million (+6% year-over-year); net profit: €356.2 million (+14%).

• EBITDA: €520.1 million (+3%); EBIT: €427.6 million (+7%).

• Gross profit margin: 57.3% (up 0.5 pp); net profit margin: 18.7% (up 1.3 pp).

• Cash and cash equivalents nearly doubled to €344.9 million.

• Dividend per share increased 14% to €7.50; share price up 26% to €139.00.

Outlook and guidance

• Continued investment in production capacity, R&D, and sustainability initiatives.

• Ongoing expansion in international markets, with a focus on Eastern and Central Europe and new ventures in India.